Skip to contentSkip to main content

Glucose, cholesterol, weight and interactions · Evidence guide

Berberine: evidence-based benefits, dose, forms and safety

Berberine can produce modest short-term improvements in fasting glucose, HbA1c, LDL cholesterol and triglycerides in some adults with metabolic disease, but trials are heterogeneous and do not prove fewer heart attacks, diabetes complications or longer life.

It is not ‘natural Ozempic’: a strong 2026 trial found no reduction in visceral fat or liver fat after six months. Because it can interact with medicines and poses pregnancy, newborn and transplant risks, a medication review matters more than chasing the biggest dose.1,2,3,6,7,8,9,12,13

Strong
Updated August 11, 202638 min readHuman evidence first
Unbranded pale capsules beside botanical root and a molecular lattice on cream and deep navy surfaces with one bright LongevityMate orange accent

At a glance

Berberine

Overall evidence
Modest short-term metabolic biomarker effects; no proven long-term clinical-outcome benefit2,8,9,10ModerateFinding: mixed results
Blood sugar
Fasting glucose about 0.52 mmol/L lower and HbA1c about 0.41 percentage point lower on average in one meta-analysis8ModerateFinding: small benefit
LDL cholesterol
About 0.46 mmol/L (18 mg/dL) lower on average across short placebo-controlled trials9ModerateFinding: small benefit
Weight loss
Not established; a 337-person six-month trial found no visceral-fat or liver-fat benefit1,6,7StrongFinding: no meaningful benefit
Heart and diabetes outcomes
No proof of fewer heart attacks, kidney failure, neuropathy, retinopathy or deaths8,9,10StrongFinding: still unknown
Typical studied range
Usually 900–1,500 mg/day of standard berberine, divided, for roughly 8–12 weeks8,9,11ModerateFinding: established use
Best-supported form
Standard berberine, commonly HCl, because most human glucose and lipid biomarker trials used it—not because it absorbs best8,9,11,14,15,16ModerateFinding: benefit supported
Interaction risk
Human evidence shows CYP2D6, CYP2C9 and CYP3A4 effects and increased cyclosporine exposure12,13StrongFinding: established use
Do not self-start
Pregnancy, breastfeeding, infants, children, transplant care or complex medication treatment2,3,4,13,26StrongFinding: established use
Product quality
In one US assay, 9 of 15 products failed the study’s 90%–110% label-potency benchmark17,18StrongFinding: mixed results

Study findings describe groups, not a guaranteed result for one person.

Research and writing

LongevityMate Editorial Team

Editorial oversight

Lukas Dvorsky, Founder

Clinical review

Not yet assigned or claimed